JP2009545598A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009545598A5 JP2009545598A5 JP2009522869A JP2009522869A JP2009545598A5 JP 2009545598 A5 JP2009545598 A5 JP 2009545598A5 JP 2009522869 A JP2009522869 A JP 2009522869A JP 2009522869 A JP2009522869 A JP 2009522869A JP 2009545598 A5 JP2009545598 A5 JP 2009545598A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- carbon
- hydrogen
- substituted
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 77
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 30
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 27
- 229910052799 carbon Inorganic materials 0.000 claims 27
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- -1 cyano, nitro, hydroxy, amino Chemical group 0.000 claims 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000003302 alkenyloxy group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 125000006766 (C2-C6) alkynyloxy group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000005133 alkynyloxy group Chemical group 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82111606P | 2006-08-01 | 2006-08-01 | |
| PCT/US2007/017244 WO2008016675A1 (en) | 2006-08-01 | 2007-08-01 | P38 kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009545598A JP2009545598A (ja) | 2009-12-24 |
| JP2009545598A5 true JP2009545598A5 (enExample) | 2010-09-16 |
Family
ID=38705006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009522869A Pending JP2009545598A (ja) | 2006-08-01 | 2007-08-01 | Ｐ３８キナーゼ阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8119798B2 (enExample) |
| EP (1) | EP2059512A1 (enExample) |
| JP (1) | JP2009545598A (enExample) |
| WO (1) | WO2008016675A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2440052A4 (en) * | 2009-06-08 | 2013-01-23 | Abraxis Bioscience Llc | TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF |
| AU2011260323A1 (en) | 2010-06-04 | 2012-11-15 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as LRRK2 modulators |
| DK2638031T3 (en) | 2010-11-10 | 2017-12-11 | Genentech Inc | PYRAZOLAMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS |
| US20120295911A1 (en) | 2010-11-29 | 2012-11-22 | Galleon Pharmaceuticals, Inc. | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases |
| CA2819333A1 (en) * | 2010-11-29 | 2012-06-07 | Galleon Pharmaceuticals, Inc. | Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases |
| WO2020124213A1 (en) | 2018-12-20 | 2020-06-25 | Krylov Sergey N | Binder selection using capillary electrophoresis |
| EP3772513A1 (en) * | 2019-08-09 | 2021-02-10 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | Shp2 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1053230A1 (en) | 1998-01-13 | 2000-11-22 | Scriptgen Pharmaceuticals, Inc. | Triazine antiviral compounds |
| US6262053B1 (en) | 1999-06-23 | 2001-07-17 | Parker Hughes Institute | Melamine derivatives as potent anti-cancer agents |
| JP2003519143A (ja) * | 1999-12-28 | 2003-06-17 | ファーマコピーア，インコーポレーティッド | ピリミジン及びトリアジン系キナーゼ阻害剤 |
| EP1409463B1 (en) * | 2001-06-26 | 2010-02-24 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
| HUP0401711A3 (en) | 2001-06-26 | 2009-07-28 | Bristol Myers Squibb Co | N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them |
| US7173032B2 (en) | 2001-09-21 | 2007-02-06 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
| EP1441683A4 (en) | 2001-10-12 | 2005-10-26 | Univ New York | TRISUBSTITUTED TRIAZIN COMPOUNDS AND METHOD FOR THE PREPARATION AND USE OF THE COMPOUNDS WITH ANTITUBULIN EFFECT |
| FR2841116B1 (fr) | 2002-06-19 | 2004-11-26 | Seb Sa | Cafetiere du type expresso a reservoir d'eau amovible |
| JP2006516561A (ja) | 2003-01-17 | 2006-07-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類 |
| CA2608463C (en) | 2005-05-19 | 2015-02-03 | Prometic Biosciences Inc. | Compounds, compositions containing such compounds, and methods of treatment of metastatic melanoma and other cancers |
| EP2441757A1 (en) * | 2006-07-31 | 2012-04-18 | Praecis Pharmaceuticals Incorporated | Aurora kinase inhibitors from an encoded small molecule library |
-
2007
- 2007-08-01 WO PCT/US2007/017244 patent/WO2008016675A1/en not_active Ceased
- 2007-08-01 US US12/375,184 patent/US8119798B2/en active Active
- 2007-08-01 EP EP07811002A patent/EP2059512A1/en not_active Withdrawn
- 2007-08-01 JP JP2009522869A patent/JP2009545598A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009545598A5 (enExample) | ||
| NZ594332A (en) | Compounds for the prevention and treatment of cardiovascular disease | |
| JP2011529049A5 (enExample) | ||
| JP2010525056A5 (enExample) | ||
| WO2012147107A3 (en) | Novel & improved processes for preparing indoline derivatives and its pharmaceutical composition | |
| EP2620432A3 (en) | Diarylhydantoin compounds | |
| SI3009431T1 (en) | 2- (2,4,5-substituted-anilino) pyrimidine derivatives, as EGFR modulators useful for the treatment of cancer | |
| JP2016522835A5 (enExample) | ||
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| GEP20125469B (en) | Inhibitors of akt activity | |
| JP2015517566A5 (enExample) | ||
| NZ588830A (en) | Inhibitors of protein kinases | |
| JP2014526549A5 (enExample) | ||
| CA2687265A1 (en) | P70 s6 kinase inhibitors | |
| JP2014505107A5 (enExample) | ||
| JP2017504611A5 (enExample) | ||
| JP2016526540A5 (enExample) | ||
| RU2011108026A (ru) | Комбинированная терапия туберкулеза | |
| JP2009512719A5 (enExample) | ||
| TW200738729A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| JP2011513410A5 (enExample) | ||
| AU2014310371A1 (en) | Compositions and therapeutic methods for accelerated plaque regression | |
| JP2011521938A5 (enExample) | ||
| TN2012000110A1 (en) | N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer | |
| JP2006501201A5 (enExample) |